Eye Disease Treatment

Regeneron Stock Plummets as FDA Delays Blockbuster Release and Rejects High-Dose Eylea

Regeneron Pharmaceuticals' stock slumped after the FDA rejected its application for approval of a higher-dose version of its popular eye disease treatment, Eylea.